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Supplementary Methods
For the ADR-induced nephritis model, BALB/c mice were given a single injection of
Adriamycin (ADR,10 mg/kg) via retro-orbital injection. BALB/c mice were obtained from
CLEA, Inc. (Tokyo, Japan). Metformin (5 mg/ml in drinking water) or vehicle was orally given
to the ADR nephritis mice from day 1 after ADR injection until day 28. Metformin was
purchased from Wako Pure Chemical Industries (Tokyo, Japan) and ADR was purchased from




Supplementary Figure S1. Metformin did not affect the body weight, water intake and urine
volume
(a) Body weight, (b) water intake and (c) urine volume were measured every four weeks. Urine
volume was measured using metabolic cages for 24 hr. Bars indicate the mean ± S.E. (n=8-9).
Supplementary Figure S1 
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Supplementary Figure S2 
Supplementary Figure S2. Metformin did not affect the blood glucose and serum
lactate levels
(a) Blood glucose level was measured at 8 weeks of treatment with ACCU-CHEK Compact
(Roche Diagnostic, Mannheim, Germany). (b) Serum lactate level was measured at 10
weeks of treatment using L-Lactate Assay kit (Ab65331, Abcam). Bars indicate the mean


































































































































































































































Supplementary Figure S3 








































































































































































































































































































































































































































































































































































































































































































Supplementary Figure S3. Transcriptome analysis of kidney revealed the comprehensive effects
of metformin on CKD in Col4a5 G5X-Alport syndrome mice
Heat map shows the fluctuated genes associated with inflammation, matrix, metabolism and FSGS in
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Supplementary Figure S4. Metformin-specific altered genes in
kidney of Col4a5 G5X-Alport syndrome mice
(a) Pathway analysis of metformin-specific altered genes. (b) Heat map
shows the altered genes in Alport metformin group compared with
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Supplementary Figure S5. Losartan-specific altered genes in kidney of Col4a5 G5X-
Alport syndrome mice
(a) Pathway analysis of metformin-specific altered genes. (b) Heat map shows the altered
genes in Alport losartan group compared with Alport vehicle (<-2, 2<, P value < 0.05)



















































































































































































































































































































































































































































































































































































































































































































































Supplementary Figure S6. Transcriptome analysis revealed the comprehensive effects of
metformin on glomerular nephritis in glomerulus of Col4a5 G5X-Alport syndrome mice
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Supplementary Figure S7. Metformin-specific altered genes in the glomerulus of Col4a5
G5X-Alport syndrome mice
(a) Pathway analysis of metformin-specific altered genes. (b) Heat map shows the altered genes in
Alport metformin group compared with Alport vehicle (<-2, 2<, P value < 0.05) which did not
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Supplementary Figure S8. Losartan-specific altered genes in the glomerulus of Col4a5 G5X-
Alport syndrome mice
(a) Pathway analysis of losartan-specific altered genes. (b) Heat map shows the altered genes in
Alport losartan group compared with Alport vehicle (<-2, 2<, P value < 0.05) which did not
change in Alport metformin group.
C57BL6 strain
Col4a5 G5X





















Supplementary Figure S9. Scheme of the treatments in mice for the survival study
(a) Col4a5 G5X-Alport syndrome mice were treated with the indicated dose of losartan or
metformin until all mice died. (b) Col4a3-/- Alport syndrome mice were treated with the indicated







































Supplementary Figure S10. Metformin protects against ADR-induced glomerulosclerosis
(a) Proteinuria score was calculated based on urinary protein and creatinine concentrations. Metformin
reduced proteinuria in ADR nephropathy model. (b) Staining of renal sections was performed using
PAS. Scale bar, 50 m. (c) Glomerular injury scores were assigned based on the PAS-stained sections.
Metformin ameliorated the severity of glomerulosclerosis in ADR nephropathy. Data are expressed as
the means ± S.E. in control mice (n = 4), non-treated ADR, and metformin-treated ADR mice (n = 10
per group), P values were assessed by Dunnett’s test (#P < 0.05, ##P < 0.01 vs CON, *P < 0.05, **P <
0.01 vs ADR). (d) Whole kidney lysates were analyzed by immunoblotting. The full-length blots are
presented in Supplementary Fig. S13. (e-g) The relative amount of proteins was quantified. Metformin
increased the level of (e) phospho-AMPK and (g) Nrf2. Metformin decreased the level of (f) phospho-
STAT3. Data are expressed as the means ± S.E. (n = 4 per group). P values were assessed by Student’s t
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Supplementary Figure S11. Full length blots for Figure 2m
The full-length blots for Figure 2m with the indicated antibodies. Vinculin was used as loading
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Figure S12. Full length blots for Figure 3a
The full-length blots for Figure 3a with the indicated antibodies. Vinculin was used as loading control.















































































Supplementary Figure S13. Full length blots for Supplementary Figure S10d
The full-length blots for Supplementary Fig. 10d with the indicated antibodies. Vinculin was used as
loading control. Samples were derived from the same experiment, and gels/blots were processed in
parallel.
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